Next Article in Journal
How Postural Muscle Senses Disuse? Early Signs and Signals
Previous Article in Journal
Seeding and Growth of β-Amyloid Aggregates upon Interaction with Neuronal Cell Membranes
Previous Article in Special Issue
Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
Review

Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications

1
Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
2
Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
3
Biomedical Sciences Institute Abel Salazar (ICBAS), University of Porto, 4200-072 Porto, Portugal
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 5036; https://doi.org/10.3390/ijms21145036
Received: 18 June 2020 / Revised: 10 July 2020 / Accepted: 13 July 2020 / Published: 16 July 2020
Prostate cancer (PrCa) ranks among the top five cancers for both incidence and mortality worldwide. A significant proportion of PrCa susceptibility has been attributed to inherited predisposition, with 10–20% of cases expected to occur in a hereditary/familial context. Advances in DNA sequencing technologies have uncovered several moderate- to high-penetrance PrCa susceptibility genes, most of which have previously been related to known hereditary cancer syndromes, namely the hereditary breast and ovarian cancer (BRCA1, BRCA2, ATM, CHEK2, and PALB2) and Lynch syndrome (MLH1, MSH2, MSH6, and PMS2) genes. Additional candidate genes have also been suggested, but further evidence is needed to include them in routine genetic testing. Recommendations based on clinical features, family history, and ethnicity have been established for more cost-efficient genetic testing of patients and families who may be at an increased risk of developing PrCa. The identification of alterations in PrCa predisposing genes may help to inform screening strategies, as well as treatment options, in the metastatic setting. This review provides an overview of the genetic basis underlying hereditary predisposition to PrCa, the current genetic screening recommendations, and the implications for clinical management of the disease. View Full-Text
Keywords: prostate cancer; hereditary cancer syndrome; genetic testing; germline variants prostate cancer; hereditary cancer syndrome; genetic testing; germline variants
Show Figures

Figure 1

MDPI and ACS Style

Brandão, A.; Paulo, P.; Teixeira, M.R. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int. J. Mol. Sci. 2020, 21, 5036. https://doi.org/10.3390/ijms21145036

AMA Style

Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. International Journal of Molecular Sciences. 2020; 21(14):5036. https://doi.org/10.3390/ijms21145036

Chicago/Turabian Style

Brandão, Andreia, Paula Paulo, and Manuel R. Teixeira 2020. "Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications" International Journal of Molecular Sciences 21, no. 14: 5036. https://doi.org/10.3390/ijms21145036

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop